Male breast cancer; analysis of 58 cases in Shiraz, South of Iran.
male breast cancer (MBC) is very rare and accounts for less than one percent of all cancers in men. Because of the low incidence of MBC it has not attracted extensive studies. The current study is the first cohort of men with breast carcinoma reported in our country to date. We retrospectively reviewed the medical records of 58 MBC patients who had been treated at Shahid Faghihi Hospital in Shiraz, Iran, between 1990 and 2007. Data regarding general characteristics of patients including: age at time of diagnosis, family history of breast cancer, site, stage, size and location of tumor, histopathology of primary tumor, and treatment modalities (surgery, chemotherapy, radiation and hormone therapy) were obtained by reviewing medical records. among 58 MBC patients included in current study, 98.3% of patients were presented with a palpable mass, while 22.4% had breast skin deformity, and 12.1% patients had breast discharge. The median age at time of diagnosis was 60 years (range, 34-84 years). Infiltrative ductal carcinoma was found in 96.2% of patients, insitu ductal carcinoma in 3.8% of patients. The histopathological diagnosis of 5 breast tumors was missed. 4.3% of tumors were diagnosed in stage 0, 10.6% in stage one, 74.5% in stage two, and 10.6% in stage three. Regional lymph node involvement were diagnosed in 20.7% of patients, and 15.5% patients had distant metastasis at the time of diagnosis. this study, in spite of limitations, suggests that the incidence of MBC is increasing, and men are diagnosed with later-stage disease than women. Therefore, MBC screening should become a part of female breast cancer registry system.